Despite New Launches, Teligent Sees A Disappointing Q4

Company Cuts First-Quarter Projections Due To COVID-19

Amid poor quarterly results, Teligent continues to focus on resolving a warning letter from the FDA, passing a pre-approval inspection of its new injectables manufacturing facility in Buena, New Jersey and managing cash flow under its new CEO.

Red_Arrow_Downturn
Teligent sees a drop in sales • Source: Shutterstock

Despite four new launches in both the US and Canada in 2019, Teligent has reported turnover that fell by 5% to $16m in the fourth quarter. The company said that the decrease was driven primarily by “a decline in both US contract manufacturing and international injectable revenues, partially offset by a 24% increase in US Teligent-label topical revenues.”

However, on an annual basis sales in 2019 remained flat at $65.9m, “although the mix of where revenues originated changed...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business